The Hidden Art of Disintermediation: Why Markets Break When Buyers Stop Acting Like Afterthoughts

What happens when the buyer refuses to be a passive node?

For years, many markets have been built on a quiet assumption: the buyer will not, and perhaps cannot, organize the full chain of value. Someone else will aggregate demand, negotiate access, simplify decisions, and keep the machine moving. That assumption works until the buyer becomes sophisticated enough to ask a dangerous question: what exactly am I paying for, and who is really coordinating this relationship?

That question is reshaping pharmaceutical purchasing, and it is also the same question that underlies the most effective account based marketing programs. In both cases, the old model depends on intermediaries claiming expertise while controlling information, access, and decision flow. In both cases, the counter move is not merely to remove the middle layer. It is to rebuild the buying process around the real unit of value, whether that unit is a patient, an employer, or a target account.

The deeper tension is this: intermediation creates efficiency until it begins to obscure accountability. At that point, the market does not just want lower costs. It wants transparency, control, and a direct line of sight from decision to outcome. The companies that understand this shift do not just sell differently. They redesign the structure of exchange itself.

---

The real conflict is not middlemen versus no middlemen

It is tempting to describe these shifts as simple disintermediation stories. Remove the PBM, remove the friction. Remove the generic ABM vendor playbook, remove the noise. But that framing misses the deeper pattern. The point is not that all intermediaries are bad. The point is that intermediaries become fragile when they no longer own the complexity they were hired to manage.

In pharmaceutical purchasing, the PBM was built to centralize formulary management, rebates, and access. That made sense in a fragmented world. But once employers begin to suspect that rebate logic may be shaping behavior in ways that are not aligned with their interests, the intermediary loses something more important than margin. It loses trust. And when trust erodes, buyers stop asking, “How do we use this system better?” They start asking, “Can we replace the system?”

That same inflection point appears in account based marketing. A broad ABM motion often fails not because the concept is wrong, but because the program has become an intermediary between sales intent and real buyer needs. If it is just a layer of personalization theater, aimed at a wish list of accounts with no clear qualification, no research discipline, and no ownership, it does not create clarity. It creates ceremony.

The fatal flaw of weak intermediation is not cost, it is abstraction.

The buyer cannot tell whether the process is producing value or merely moving information around. Once that happens, the market begins to search for more direct contracts, tighter segments, and better evidence. In other words, it starts to demand a better architecture of buying.

---

The best response to complexity is not simplification. It is precision.

Here is the counterintuitive truth: when a market becomes more complex, the winning response is often not to reduce complexity everywhere. It is to move complexity to the places where it creates leverage.

That is why direct contracting in pharma is so interesting. Large employers do not eliminate complexity. They absorb it. They take on the work of formulary design, manufacturer negotiation, pharmacy relationships, and payment structures. That is a serious operational burden. But in exchange, they reclaim control over pricing credits, rebate flows, and treatment design. They stop renting a black box and start engineering a system.

ABM works the same way when it is operationalized properly. Real personalization is not a shiny message. It is a structured understanding of an account’s strategic priorities, challenges, jobs to be done, and stage in the buyer journey. That requires segmentation, qualification criteria, account research, awareness design, development motions, and activation paths. It is more work than generic demand generation. But the payoff is that you are no longer guessing at relevance. You are designing for it.

Think of the difference like this:

• A weak intermediary says: “Trust us, we know the market.”
• A strong direct model says: “We know exactly what matters to us, and we have built the system around that.”

That shift matters because it changes who holds the operating knowledge. In the old model, the intermediary is the expert and the buyer is dependent. In the new model, the buyer becomes the system designer. That is why employer coalitions matter so much in pharma. They do not merely increase purchasing power. They create the shared infrastructure needed to do what a single buyer could not do alone.

The ABM parallel is striking. Small and midsize teams often fail not because account based thinking is wrong, but because they lack the organizational scaffolding: formed ABM team, defined goals, cluster selection, win loss analysis, documented playbook, and clear measurement. Without that infrastructure, “personalization” turns into random acts of relevance.

Precision is what happens when a buyer stops asking for a generic solution and starts describing the exact job that must be done.

---

The coalition is the missing bridge between scale and control

One of the most important ideas connecting these two worlds is the role of the coalition. In pharma, employer coalitions allow smaller organizations to do what only giant employers could previously do: negotiate directly, explore creative contracts, and test alternative models. In ABM, the equivalent is the internal coalition that aligns marketing, sales, operations, and leadership around a shared account strategy.

This is more than a governance detail. It is how disintermediation becomes feasible without becoming chaotic.

A single large employer can sometimes build direct contracting capability alone. But most buyers cannot. They need collective scale. Similarly, a single marketer cannot create real account based transformation if sales does not share the same qualification criteria, if operations cannot track engagement, or if leadership cannot define success. The coalition is what turns intent into operating power.

This is where many transformations fail. They assume disintermediation means bypassing structure. In reality, it often means creating a better structure than the old one.

Consider a useful analogy. A PBM is like a train station that routes millions of passengers through a centralized timetable. It is efficient when the routes are stable. But when passengers begin to need custom routes, special handling, milestone-based payments, or value-based treatment journeys, the station model starts to buckle. Direct contracting does not mean abandoning scheduling. It means building a different routing system for different kinds of trips.

ABM has the same dynamic. Not every account deserves the same motion. Some are cluster ICP accounts, where awareness is low and product need is uncertain. Some are future pipeline accounts, where awareness exists but need is not yet proven. Some are active focus accounts, where both awareness and need are present. If you treat them all the same, you create waste. If you segment them properly, you create motion that matches maturity.

The coalition makes that matching possible because it shares the cost of knowing.

---

The future belongs to systems that can prove value at the account level

Both examples point toward the same underlying shift in market design: buyers increasingly want value to be legible at the smallest meaningful unit. In pharma, that may be an individual therapy, a chronic disease pathway, or a consumer purchase. In B2B growth, it may be a single account, a buying committee, or a named cluster of target firms.

This is why the rise of direct to consumer e commerce in prescriptions matters. It is not merely a retail convenience story. It is a signal that people are willing to bypass institutional complexity when the value proposition is simple enough and the transaction can be made legible. For lifestyle drugs, the consumer can see the benefit, compare prices, and pay cash. The stack gets shorter because the decision is cleaner.

In ABM, the analogue is the account that can finally see itself in your offer. Not in a vague “we help companies like yours” way, but in a specific “we understand your initiative, your KPI, your stakeholder map, and your likely internal friction” way. That is when engagement begins to feel less like outreach and more like diagnosis.

This suggests a new framework: value legibility.

A market is ripe for disintermediation when three things become true:

1. The buyer can name the value problem clearly.
2. The buyer can measure the result without relying on the intermediary’s story.
3. The buyer has enough coordination power, alone or in coalition, to act directly.

When those three conditions align, the intermediary is no longer the owner of truth. It becomes optional, specialized, or replaceable.

That is why the most resilient intermediaries of the future will not be opaque gatekeepers. They will be enablers of precision. They will supply data, coordination, compliance, and execution in ways that make directness safer, faster, and more trustworthy. In other words, the best intermediaries will behave less like toll booths and more like infrastructure.

---

The practical lesson: stop selling channels, start designing decision systems

If there is a single takeaway from the overlap of these ideas, it is this: the winning strategy is no longer to maximize contact. It is to design the decision environment.

In pharma, that means asking where a PBM adds genuine administrative leverage and where it merely inserts cost or opacity. Maybe the answer is full direct contracting for some employers, limited contracting for high cost therapies, coalition based purchasing for smaller firms, and direct to consumer channels for low complexity prescriptions. The point is not ideological purity. The point is architectural fit.

In ABM, the same logic applies. The question is not whether you are “doing ABM.” The question is whether your account motion actually changes how a buying group experiences relevance, trust, and urgency. That requires:

• a defined program goal,
• a defined target cluster,
• a disciplined qualification model,
• deep account research,
• an awareness plan that matches buyer maturity,
• a development sequence that builds relationships,
• and an activation path that makes the next step obvious.

Most organizations collect fragments of these elements but never assemble them into a system. As a result, they mistake activity for orchestration. A few personalized emails, some intent data, and a monthly pipeline review do not make a strategy. They make noise with better typography.

The better question is: what is the buyer trying to do that the current market structure makes unnecessarily hard?

That question forces clarity. It reveals where intermediaries create value and where they merely preserve old assumptions. It also shifts the conversation from channel preference to problem solving. Buyers do not want more channels. They want fewer hidden costs, fewer blind spots, and fewer excuses between decision and outcome.

The future of go to market is not about being closer to the customer in a sentimental sense. It is about making the customer’s choices more executable.

---

Key Takeaways

1. Do not confuse intermediation with value. A middle layer is useful only when it reduces complexity better than the buyer can.
2. Build precision before scale. Whether in pharma purchasing or ABM, the winning move is to understand the exact decision environment before expanding reach.
3. Coalitions are the bridge to directness. Smaller buyers need shared infrastructure to act with the power of larger ones.
4. Segment by decision maturity, not just firmographics. Accounts and buyers need different motions depending on awareness, need, and readiness.
5. Measure value at the smallest meaningful unit. If the outcome cannot be seen at the account, therapy, or consumer level, the system is probably too opaque.

---

Conclusion: the market always drifts toward the buyer who can organize itself

The deepest lesson connecting these two domains is not about pharmaceuticals or marketing. It is about power. Markets reward the party that can best organize complexity around a clear demand. For a long time, intermediaries held that power because they were the only entities capable of turning chaos into transactions.

But that advantage is weakening. Employers are building coalitions. Consumers are self directing purchases. B2B teams are learning to qualify accounts, research buying committees, and activate offers with surgical specificity. The center of gravity is moving toward the buyer that can see itself clearly enough to act directly.

That does not mean intermediaries disappear. It means they must earn their place by making the buyer sharper, not more dependent. The future belongs to systems that help people understand what they need, prove what works, and execute with less ambiguity.

In that sense, disintermediation is not really about removing the middle. It is about removing the fog.